Research graph
References from Changes in serum potassium with concomitant administration of renin-angiotensin system agents and potassium-sparing diuretics: U.S. cohort study using electronic health record data. Local targets link to admitted publications; unresolved targets remain external evidence.
The global epidemiology of hypertension
10.1038/s41581-019-0244-2 · 2020 · External reference
Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension blood pressure/hypertension guidelines
10.1093/eurheartj/ehac432 · 2022 · External reference
Mega clinical trials which have shaped the RAS intervention clinical practice
10.1177/1753944716644131 · 2016 · External reference
Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
10.1111/j.1476-5381.2010.00750.x · 2010 · External reference
Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis
10.1016/j.ahj.2008.01.031 · 2008 · External reference
Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010
10.1161/circulationaha.112.096156 · 2012 · External reference
The utilization, expenditure, and price of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the US Medicaid programs: trends over a 31 year period
10.1016/j.ijcard.2022.10.152 · 2023 · External reference
Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease
2018 · External reference
Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice
10.1002/ejhf.226 · 2015 · External reference
Antihypertensive medications and the prevalence of hyperkalemia in a large health system
10.1161/hypertensionaha.116.07363 · 2016 · External reference
Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs
10.5507/bp.2012.087 · 2014 · External reference
Drug-induced hyperkalemia
10.1007/s40264-014-0196-1 · 2014 · External reference
Hyperkalemia
2006 · External reference
Advances in treatment of hyperkalemia in chronic kidney disease
10.1517/14656566.2015.1083977 · 2015 · External reference
Hyperkalemia in hospitalized patients
10.1023/a:1007135517950 · 2000 · External reference
Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors
10.1159/000013599 · 2000 · External reference
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone
10.1093/ndt/gfg295 · 2003 · External reference
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
10.1186/1756-0500-6-306 · 2013 · External reference
Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors for the treatment of arterial hypertension and the role of olmesartan
10.1007/s12325-018-0859-x · 2019 · External reference
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
2009 · External reference
Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure
10.14797/mdcj-11-4-235 · 2015 · External reference
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
10.1056/nejm199909023411001 · 1999 · External reference
A comparison of the aldosterone-blocking agents eplerenone and spironolactone
10.1002/clc.20324 · 2008 · External reference
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
10.1056/nejmoa030207 · 2003 · External reference
Overriding of drug safety alerts in computerized physician order entry
10.1197/jamia.m1809 · 2006 · External reference
Physicians' decisions to override computerized drug alerts in primary care
10.1001/archinte.163.21.2625 · 2003 · External reference
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)
10.1136/bmj.k3532 · 2018 · External reference
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population-and insurance-based cohort
10.1002/pds.3748 · 2015 · External reference
Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system
10.1056/nejmra035279 · 2004 · External reference
Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs
10.1007/s00228-011-1028-1 · 2011 · External reference
Drug-drug interactions among elderly patients hospitalized for drug toxicity
10.1001/jama.289.13.1652 · 2003 · External reference
Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients
10.1177/1753944715591448 · 2015 · External reference
Treatment of resistant and refractory hypertension
10.1161/circresaha.118.312156 · 2019 · External reference
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial
10.2337/diacare.26.8.2268 · 2003 · External reference
Efficacy and safety of renin-angiotensin aldosterone system inhibitor in patients with IgA nephropathy: a meta-analysis of randomized controlled trials
2019 · External reference
Angiotensin blockade in late autosomal dominant polycystic kidney disease
10.1056/nejmoa1402686 · 2014 · External reference
Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: a nationwide cohort study
10.1111/jch.14224 · 2021 · External reference
Unresolved reference
2022 · External reference
How dangerous is hyperkalemia?
10.1681/asn.2016121344 · 2017 · External reference
Clinical factors associated with hyperkalemia in patients with congestive heart failure 1
10.1111/j.1365-2710.2005.00638.x · 2005 · External reference
Eplerenone in patients with systolic heart failure and mild symptoms
10.1056/nejmoa1009492 · 2011 · External reference
Real-world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom
2019 · External reference
Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes
10.1159/000479802 · 2017 · External reference
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies
10.1161/circheartfailure.109.899526 · 2010 · External reference
2020 International Society of Hypertension global hypertension practice guidelines
10.1161/hypertensionaha.120.15026 · 2020 · External reference
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: a systematic review and meta-analysis
10.1093/ajhp/zxab215 · 2021 · External reference
ACE inhibitor and ARB therapy: practical recommendations
10.3949/ccjm.86a.19016 · 2019 · External reference
Research and reporting considerations for observational studies using electronic health record data
10.7326/m19-0873 · 2020 · External reference
